BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, July 18, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Trump administration impacts continue to roil the life sciences sectorBreaking News: Self-amplifying mRNA technology underscored for next big pandemic
  • Transmission electron micrograph of HIV-1 virus particles

    IAS 2025: Cheat, parasitize, break the virus – fresh ideas fuel HIV research

    There is still no effective vaccine or cure for HIV. Scientists are considering options ranging from longer-term antiretroviral therapy (ART) that space out injections by several years to long-lasting pre-exposure prophylaxis (PrEP) that acts as a vaccine while immunization is achieved. What else can be done? The “Innovations in HIV virology: Translating discoveries into novel therapies” symposium in basic science at the 13th IAS Conference on HIV Science (IAS 2025), which took place from July 13 to 17, 2025, in Kigali, Rwanda, showcased some of the new ideas that the scientific community are developing.
  • TRPC1 mediates pathological plasticity in fragile X syndrome mice

  • CAR-expressing natural killer cells to combat rhabdomyosarcoma

  • SK Bioscience submits IND for adjuvanted flu vaccine

  • IAS 2025: Cheat, parasitize, break the virus – fresh ideas fuel HIV research

    There is still no effective vaccine or cure for HIV. Scientists are considering options ranging from longer-term antiretroviral therapy (ART) that space out injections by several years to long-lasting pre-exposure prophylaxis (PrEP) that acts as a vaccine while immunization is achieved. What else can be done? The “Innovations in HIV virology: Translating discoveries into novel therapies” symposium in basic science at the 13th IAS Conference on HIV Science (IAS 2025), which took place from July 13 to 17, 2025, in Kigali, Rwanda, showcased some of the new ideas that the scientific community are developing.
  • TRPC1 mediates pathological plasticity in fragile X syndrome mice

    Fragile X syndrome (FXS), the most common inherited cause of intellectual disability and autism, is caused by silencing of the Fmr1 gene, leading to a lack of the FMRP protein, which regulates protein synthesis in neurons. One key pathway affected by FMRP loss is the metabotropic glutamate receptor 5 (mGluR5) signaling pathway, where activation of mGluR5 leads to excessive translation of several proteins involved in synaptic plasticity. 

  • CAR-expressing natural killer cells to combat rhabdomyosarcoma

    Rhabdomyosarcoma is the most frequent cancer affecting soft tissues in children, and existing therapies often fail to stop relapse or prolong survival. Researchers in Germany and the U.K. have developed a potential new therapy based on natural killer cells expressing a chimeric antigen receptor against epidermal growth factor receptor (EGFR-CAR).
  • SK Bioscience submits IND for adjuvanted flu vaccine

    SK Bioscience Ltd. announced that the company has submitted an investigational new drug (IND) application to the South Korean Ministry of Food and Drug Safety.
  • Other news to note for July 18, 2025

    Additional early-stage research and drug discovery news in brief.
  • New vulnerability in uveal melanoma opens door to treatment advances

    In a recent study published in Nature Genetics, a team of scientists used CRISPR-Cas9 gene editing to systematically analyze genetic weaknesses in uveal melanoma cells and comprehensively map monogenic and digenic dependencies.
  • Research shows d3-T has testosterone benefits without estradiol conversion

    In drug development, replacing hydrogen atoms with deuterium may help improve the pharmacokinetic profile without altering pharmacodynamic activity.
  • Gasherbrum Bio reports new GLP-1R agonists for diabetes

    Gasherbrum Bio Inc. has patented new heterocyclic glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, among others.
  • Bi-allelic variants in POPDC2 cause cardiac conduction defects

    Researchers have identified bi-allelic variants in the POPDC2 gene as the cause of a rare inherited cardiac syndrome characterized by sinus node dysfunction, atrioventricular (AV) conduction defects and hypertrophic cardiomyopathy.
  • Spliceosome RNPC3 blockade restricts the growth of several cancer types

    Concept art for targeting cancer
  • Deciphera Pharmaceuticals patent details compounds for treatment of cancer

  • Ideaya Biosciences patents KAT6A and KAT7 inhibitors

  • Nanobody against CD155 to treat lung cancer

    Lung cancer illustration
  • Cannabinoid CB2 receptor agonists disclosed in Ensem Therapeutics patent

  • Hungarian team identifies new isochroman compounds for bacterial infections

  • Results of ADME study of the small-molecule 3CLpro inhibitor SHEN-211

    Microscope and coronavirus illustration
  • Oncolytic herpes simplex virus expressing interleukin-27 to treat gliomas

BioWorld Insider Podcast

Play buttonRobert Williamson, CEO of Triumvira Immunologics, and Hernan Bazan, CEO of South Rampart Pharma, discuss bracing for tariffs, NIH grant cuts and gifting China a biopharma leadership position.
Listen now

Conferences

  • RT-114 robotic capsule matches injectable PG-102 in preclinical study

    Endocrine/metabolic
    Incretin-based therapies have demonstrated substantial efficacy in the treatment of metabolic diseases such as obesity and type 2 diabetes but the need for frequent injections remains a major barrier to patient adherence and comfort.
  • Transmission electron micrograph of HIV-1 virus particles

    IAS 2025: All eyes still on the HIV reservoir

    Science
    While people living with HIV can lead virtually normal lives thanks to antiretroviral therapy (ART), HIV persists in a latent state within cellular reservoirs that scientists do not know how to eliminate. “Transcription is a critical step in the viral life cycle. … But there are currently no drugs...
  • Improved muscle health and glucose metabolism shown with JUV-161

    Endocrine/metabolic
    Obesity and diabetes are known risk factors for sarcopenia. Insulin resistance that occurs during type 2 diabetes promotes impaired synthesis of muscle protein and muscle breakdown. Juvena Therapeutics Inc. has presented data at ENDO 2025 conference for JUV-161, a novel secreted protein that...
  • Marea’s novel GH receptor antagonist outperforms existing treatments for acromegaly

    Endocrine/metabolic
    Acromegaly is a rare, chronic endocrine disorder characterized by excessive secretion of growth hormone (GH), most commonly resulting from a benign pituitary adenoma.
More in Conferences

Today's news in brief

  • Other news to note for July 18, 2025

  • Respiratory

  • Dermatologic

  • Cardiovascular

  • Hematologic

  • Nephrology

Patents

  • GSK prepares new compounds for treatment of cancer

  • AC Immune patent discloses new NLRP3 inflammasome inhibitors

  • VDAC1 inhibitors reported in Abarceo patent

  • Merck Sharp & Dohme discovers new PTPN1 and PTPN2 inhibitors

  • Childrens Medical Center patents new gasdermin-D activators

  • Amgen identifies new GTPase KRAS (G12D mutant) inhibitors

  • PHD inhibitors reported in Akebia Therapeutics patent

  • Black Diamond Therapeutics discloses EGFR inhibitors for cancer

  • Biosplice Therapeutics patents new DYRK1A inhibitors for Alzheimer’s disease

  • Atai Therapeutics discovers new 5-HT2A receptor partial agonists

Cancer

  • 3D illustration of tumor

    PROTAC-mediated DDR1 degradation unlocks tumor immunity

    Degradation inducer
    Discoidin domain receptor tyrosine kinase 1 (DDR1) contributes to tumor progression by promoting the alignment and densification of collagen fibers within the extracellular matrix (ECM), thereby facilitating the development of an immune-excluded tumor microenvironment (TME).
  • Chinese researchers develop potent piperine derivative for breast cancer

  • DS-3939a ADC for treating TA-MUC1-expressing tumors

    Antibody-drug conjugate
  • AGC presents new EP4 antagonists

    Patents
  • Arrakis Therapeutics patents new c-Myc inhibitors

    Patents
More in Cancer

Infection

  • Creative rendition of SARS-CoV-2 virus particles.

    New mRNA vaccine demonstrates preclinical activity against emerging SARS-CoV-2 variants

    Coronavirus
    As of May 2023, the WHO recommends the use of a monovalent XBB.1 descendent lineage, such as omicron XBB.1.5, as the vaccine antigen for COVID-19 vaccines. However, BA.2.86 and its descendent lineages, such as JN.1, have emerged and rapidly spread worldwide.
  • New antisense oligonucleotide as broad-spectrum antiviral against SARS-CoV-2

    Coronavirus
    Researchers in France and Chile have developed antisense oligonucleotide ASO-N1 against the viral RNA encoding the nucleocapsid.
  • Monoclonal antibody cross-neutralizes Nipah and Hendra viruses by targeting conserved regions

    Monoclonal antibody

    Nipah (NiV) and Hendra (HeV) viruses, two closely related members of the Henipavirus genus, continue to raise global concern due to their high mortality rates and potential for zoonotic spillover. Despite repeated outbreaks, there are still no licensed antiviral treatments targeting these...

  • Latvian Institute of Organic Synthesis describes new PfSUB1 inhibitors for malaria

    Patents
  • LAVR-289 protects against lethal adenoviral infection in the preclinical setting

  • BDGR-164 protects against lethal alphavirus infection and neuroinflammation

  • Shanghai Curegene Pharmaceutical discovers new nucleoside prodrugs for viral infections

    Patents
More in Infection

Neurology/psychiatric

  • FDA grants orphan drug designation to Amphix Bio’s AMFX-200

    Regulatory
    Amphix Bio LLC has been granted U.S. FDA orphan drug designation for its lead candidate AMFX-200 for the treatment of acute spinal cord injury (SCI). AMFX-200 is an FGFR (fibroblast growth factor receptor) and ITGB1 (integrin β1) agonist peptide amphiphile scaffold. In preclinical models of acute...
  • Brain and DNA

    Voyager Therapeutics adds new gene therapy to Alzheimer’s program

    Gene therapy
    Voyager Therapeutics Inc. has expanded its Alzheimer’s disease (AD) pipeline with the addition of a wholly owned program that modulates the expression of apolipoprotein E (APOE). Using a proprietary intravenous-delivered, blood-brain barrier (BBB)-penetrant Tracer capsid, the product delivers a...
  • Amyloid plaques on nerve cell

    Illimis $42M series B to spur study of Aβ-clearing fusion protein

    Financings
    Illimis Therapeutics Inc. raised ₩58 billion (US$42 million) in a series B financing round. The funds will support development of ILM-01, its lead bispecific fusion protein candidate, into preclinical development for Alzheimer’s disease by the second half of 2025, along with the company’s...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Acumen and JCR enter collaboration to develop BBB-penetrating Alzheimer’s treatment

    Collaboration
    Acumen Pharmaceuticals Inc. and JCR Pharmaceuticals Co. Ltd. have entered a collaboration, option and license agreement to develop a novel therapeutic candidate for the treatment of Alzheimer’s disease (AD).
  • Pfizer describes new STAT6 inhibitors

    Patents
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, atherosclerosis, metabolic dysfunction-associated steatohepatitis, respiratory and dermatological disorders.
More in Neurology/psychiatric

Immune

  • Genetic Leap to advance IL-2 modulator into clinic

  • IRF5 inhibitors show efficacy across autoimmune models

  • Oxion’s anti-OX40L antibody shows potential for disease-modifying effects

  • With surface mimicry, molecular glues shed hairpin need

  • Unnatural Products joins Argenx in a $1.5B macrocyclic deal

  • Immune checkpoint enhancer ALTB-268 decreases inflammation

  • CRVBC: Cardiac diseases can start in utero after immune migration

  • MRT-6160 VAV1 molecular glue blocks EAE in preclinical models

  • Sanofi to advance KT-485 into clinic under IRAK-4 partnership with Kymera

  • Evaxion unveils new vaccine program to prevent group A Streptococcus infections

Endocrine/metabolic

  • Diagram of how cells take up glucose from the stomach and insulin from the pancreas

    An agonist of the BMP receptor to stimulate new β-cell formation in diabetes

    Stimulating the production of β cells in the pancreas of individuals with type 1 diabetes may be a way to renormalize their glucose metabolism. Researchers from Spain and the U.S. may have moved one step closer to this goal by stimulating formation of new β cells in the pancreas of a mouse model of...
  • Palatin Technologies reports efficacy of PL-7737 in obesity model

    Regulatory
  • ARV-110 ameliorates metabolic and renal impairment in polycystic ovary syndrome

    Conferences
  • JUV-112 induces weight loss through a non-appetite-suppressing mechanism

    Conferences
  • Preclinical study uncovers dectin-1 as a potential therapeutic target to delay diabetic retinopathy

    Ocular
More in Endocrine/metabolic

Biomarkers

  • Study unveils TNFRSF9 as a marker of abdominal aortic aneurysm

    Cardiovascular
    Abdominal aortic aneurysm is a life-threatening cardiovascular disease characterized by chronic inflammation and irreversible dilatation of the abdominal aorta and is asymptomatic at the early stages of the disease, with diagnosis usually relying on imaging techniques and surgery being the main...
  • CAF22 serves as a diagnostic marker of hypertensive nephropathy

    Cardiovascular
    Hypertensive nephropathy is a major complication of hypertension characterized by inflammation and fibrosis in the kidneys. Recent findings have suggested that agrin may play a critical role in some tissue types such as in the heart or skeletal muscle.
  • Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    Science
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of the consortium which compiled it publish the proteomics signatures of major neurodegenerative diseases that they uncovered in a first...
  • FASTKD5 genetic variants tied to Leigh syndrome

    Genetic/congenital
  • Metabolic markers to predict efficacy of immune checkpoint inhibitors in non-small-cell lung cancer

    Cancer
  • miR-7974 is a predictor of poor survival in ER+ breast cancer

    Conferences
  • Taurine aging biomarker story gets more complicated

    Science
More in Biomarkers

Gastrointestinal

  • NMNAT1 confers protection in alcohol-associated liver disease

    A recent publication in Science Advances has uncovered NMNAT1 as a promising therapeutic target for alcohol-associated liver disease (ALD). Early ALD can be reversible, but prolonged alcohol abuse may lead to progressive steatohepatitis, fibrosis...
  • TLR3 inhibitor SMU-14a found to be hepatoprotective

    Toll-like receptor 3 (TLR3) has been noted to impact liver disease and promote liver inflammation. Researchers from Southern Medical University screened a natural product molecular library and found that ellipticine exerted moderate TLR3...
  • Engineered anti-IL-23 receptor antibody enables oral delivery to treat inflammatory bowel disease

    Antibody
    Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel disease in animal models.
  • Gut microbiome leads to metabolic and immune changes after transplant

    Science
    Is fecal microbiota transplant effective? Is it really safe? And is it really all the same? Scientists at the University of Chicago have investigated the regional differences in gut environments to question these interventions.
  • Korean scientists divulge new ADAMTS4 inhibitors for hepatic fibrosis

    Patents
    Researchers at Gachon University and Seoul National University Hospital have synthesized a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) inhibitors reported to be useful for the treatment of hepatic fibrosis.
  • New LPAM-1 antagonists disclosed in Dice Molecules patent

    Patents
    Dice Molecules SV LLC has divulged integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of graft-vs.-host disease, type 1 diabetes, inflammatory bowel disease, colitis and primary sclerosing cholangitis.
More in Gastrointestinal

BioWorld Insider Podcast

One-on-one with medical innovators

podcast microphone, sound waves on purple backgroundBreakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.


Recent episodes:

  • The importance of balancing AI and people in drug development
  • Two CEOs discuss bracing for tariffs, NIH grant cuts and
    gifting China biopharma leadership position
  • As biopharma investments stumble, med tech surges
  • Mega money well spent? Mammoth mergers fall short of the dream
  • Healing the health divide for women
  • Modifi gets creative on the rocky road to a multibillion-dollar buyout
  • A quantum leap into the future of drug development
  • Gene and cell therapies will propel innovation, says Astellas CCO
  • Capricor’s CEO pursues a BLA and talks rare disease
  • The first half of 2024 was strong as M&As and financings dominate

View all

BioWorld

The news source of record covering the development of innovative human therapies for 25+ years
Subscribe

BioWorld MedTech

Actionable and timely intelligence on advances in medical devices and technologies for 20+ years
Subscribe

BioWorld Asia

A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region
Subscribe

BioWorld Science

Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages
Subscribe

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription
Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing